Dr. Sartor on Conclusions and Future of Sipuleucel-T in Prostate Cancer
August 28th 2017
Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer and the potential for combinations with this agent.